genome-editing
(3)
Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a clinical-stage genomic medicine company in Brisbane, California that engineers zinc finger proteins to switch genes on, off, or rewrite them. After three decades pioneering zinc finger technology, it is racing to bring its lead gene therapy ST-920 for Fabry disease to market while building a neurology pipeline aimed at crossing the blood-brain barrier - all under the pressure of a 2026 search for strategic alternatives.
Rachel Haurwitz
Rachel Haurwitz is the President and CEO of Caribou Biosciences, a clinical-stage biopharmaceutical company she co-founded in 2011 with Nobel laureate Jennifer Doudna and colleagues Martin Jinek and James Berger. A pioneer in CRISPR commercialization, Haurwitz earned her PhD from UC Berkeley under Doudna's mentorship — she was the first student in the lab to work on CRISPR — and pivoted from academia to industry to bring genome-editing technology to patients. Under her leadership, Caribou has developed a proprietary Cas12a-based platform (chRDNA technology) enabling precise, multiplex genome editing for off-the-shelf allogeneic CAR-T and CAR-NK cell therapies targeting blood cancers and autoimmune diseases. She also co-founded Intellia Therapeutics in 2014 and has been recognized on Forbes 30 Under 30, Fortune 40 Under 40, and featured in Walter Isaacson's bestseller 'The Code Breaker.'
Sandy Macrae
Sandy Macrae is a Scottish physician-scientist who has led Sangamo Therapeutics, the Brisbane, California gene-editing pioneer, as President and CEO since June 2016. Trained at Glasgow and Cambridge - where Nobel laureate Sydney Brenner supervised his PhD - he ran emerging-markets R&D at GSK and was Global Medical Officer at Takeda before staking his career on zinc finger technology and genomic medicines for rare and neurological diseases.